Core Insights - Wex reported revenue of $691.8 million for the quarter ended September 2025, reflecting a 4% increase year-over-year and a surprise of +1.44% over the Zacks Consensus Estimate [1] - Earnings per share (EPS) for the quarter was $4.59, up from $4.35 in the same quarter last year, with an EPS surprise of +3.15% compared to the consensus estimate of $4.45 [1] Financial Performance Metrics - Average US fuel price was $3.38 per gallon, exceeding the average estimate of $3.26 per gallon [4] - Corporate Payments purchase volume was reported at $23.18 billion, slightly below the average estimate of $23.53 billion [4] - Benefits purchase volume reached $1.77 billion, compared to the average estimate of $1.85 billion [4] - Mobility payment processing transactions totaled 140 million, compared to the average estimate of 142.98 million [4] - Mobility revenues were $360.8 million, surpassing the average estimate of $350.31 million, marking a +1% year-over-year change [4] - Corporate Payments revenues were $132.8 million, below the average estimate of $144.49 million, with a +4.7% year-over-year change [4] - Benefits revenues were $198.1 million, exceeding the average estimate of $185.18 million, reflecting a +9.2% year-over-year change [4] - Corporate Payments payment processing revenues were $109.7 million, slightly above the average estimate of $109.02 million, with a +4.7% year-over-year change [4] - Benefits payment processing revenues were $23.8 million, below the average estimate of $25.06 million, with an +8.7% year-over-year change [4] - Benefits account servicing revenues were $113.3 million, close to the average estimate of $113.54 million, reflecting a +3% year-over-year change [4] - Benefits other revenues were $61 million, exceeding the average estimate of $57.99 million, with a +23.5% year-over-year change [4] - Mobility payment processing revenues were $168.2 million, below the average estimate of $172.04 million, reflecting an -8.2% year-over-year change [4] Stock Performance - Wex shares returned +0.8% over the past month, compared to the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Eos Energy Enterprises, Inc. (EOSE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus estimate of a loss of $0.29 per share, reflecting a 34.1% improvement from the previous year [1][3] - Revenues are projected to reach $39.81 million, representing a significant increase of 4583.5% compared to the same quarter last year [3] - The earnings report is anticipated to be released on November 5, and the actual results will be crucial in determining the stock's near-term price movement [2] Estimate Revisions Trend - The consensus EPS estimate has been revised 6.86% higher in the last 30 days, indicating a collective reassessment by analysts [4] - Despite the upward revision, the Most Accurate Estimate for Eos Energy is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -53.85%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Eos Energy was expected to post a loss of $0.17 per share but instead reported a loss of $1.05, resulting in a surprise of -517.65% [13] - The company has not been able to beat consensus EPS estimates in any of the last four quarters, indicating a consistent trend of underperformance [14] Bottom Line - Eos Energy does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of its earnings release [17]

Core Insights - Wall Street anticipates a year-over-year decline in earnings for NewAmsterdam Pharma Company N.V. (NAMS) due to lower revenues, with a consensus expectation of a quarterly loss of $0.38 per share, reflecting a -111.1% change from the previous year [1][3] - Revenues are projected to be $3.88 million, which is an 86.7% decrease compared to the same quarter last year [3] - The stock's price movement will largely depend on how actual results compare to these estimates, with a potential for upward movement if results exceed expectations [2] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.95% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for NewAmsterdam Pharma is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +19.13%, suggesting a likelihood of beating the consensus EPS estimate [12] Earnings Surprise History - In the last reported quarter, NewAmsterdam Pharma was expected to post a loss of $0.52 per share but actually reported a loss of -$0.15, resulting in a positive surprise of +71.15% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Drugs industry, Corcept Therapeutics is expected to report earnings of $0.18 per share, indicating a year-over-year decline of -56.1%, with revenues expected to be $219.18 million, up 20.1% from the previous year [19] - Corcept's consensus EPS estimate has been revised down by 9.7% over the last 30 days, and it has a negative Earnings ESP of -72.60%, combined with a Zacks Rank of 5 (Strong Sell), making it challenging to predict an earnings beat [20]

Core Viewpoint - Payoneer Global Inc. (PAYO) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The consensus estimate for quarterly earnings is projected at $0.06 per share, reflecting a year-over-year decrease of 45.5%, while revenues are expected to reach $263.46 million, marking a 6.1% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 19.06% higher, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Payoneer Global is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.63%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Payoneer Global currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Payoneer Global was expected to post earnings of $0.06 per share but only achieved $0.05, resulting in a surprise of -16.67% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - While Payoneer Global is viewed as a potential earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [17].

Core Insights - Praxis Precision Medicines, Inc. (PRAX) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025 [1][3] - The consensus EPS estimate for the upcoming report is a loss of $3.45 per share, reflecting a 25.5% decrease year-over-year, while revenues are expected to be $0.33 million, up 10% from the previous year [3] Earnings Expectations - The earnings report could lead to a stock price increase if the actual results exceed expectations; conversely, missing estimates may result in a stock price decline [2] - The consensus EPS estimate has been revised down by 0.5% over the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Praxis Precision Medicines is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.35%, suggesting a bullish outlook from analysts [12] - The stock currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Praxis Precision Medicines was expected to post a loss of $3.4 per share but actually reported a loss of -$3.31, achieving a surprise of +2.65% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - PTC Therapeutics (PTCT), another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.19 per share for the same quarter, which represents a year-over-year increase of 14.4% [18] - PTC Therapeutics has an Earnings ESP of +5.75% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Perrigo despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Perrigo is expected to report quarterly earnings of $0.75 per share, reflecting a year-over-year decrease of 7.4%, while revenues are projected to be $1.1 billion, an increase of 0.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.92% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Perrigo is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.33%, suggesting bearish sentiment among analysts [12]. Historical Performance - In the last reported quarter, Perrigo was expected to earn $0.59 per share but only achieved $0.57, resulting in a surprise of -3.39%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13][14]. Investment Considerations - Despite the negative Earnings ESP and Zacks Rank of 4, which complicates predictions for an earnings beat, investors are advised to consider other factors before making investment decisions [12][17].

Core Viewpoint - Wall Street anticipates flat earnings for Performance Food Group (PFGC) compared to the previous year, with a focus on revenue growth impacting stock price [1][3] Earnings Expectations - The upcoming earnings report is expected to show earnings of $1.16 per share, unchanged from the year-ago quarter, with revenues projected at $16.87 billion, reflecting a 9.4% increase [3] - A positive stock movement is likely if actual results exceed these expectations, while a miss could lead to a decline [2] Estimate Revisions - The consensus EPS estimate has been revised down by 1.5% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Performance Food is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.58% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive reading indicates a likely earnings beat, especially when combined with a Zacks Rank of 2 [10][12] - Historical performance shows that Performance Food has beaten consensus EPS estimates only once in the last four quarters, with a recent surprise of +6.90% [13][14] Conclusion - Performance Food is positioned as a strong candidate for an earnings beat, but investors should consider additional factors before making investment decisions [17]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Quantum Computing Inc. (QUBT) despite flat revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.05 per share, reflecting a year-over-year change of +16.7%, with revenues projected at $0.1 million, unchanged from the previous year [3]. - The consensus EPS estimate has been revised 16.67% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate insights [8]. - Quantum Computing Inc. has an Earnings ESP of 0%, indicating no recent differing analyst views from the consensus estimate, and currently holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Quantum Computing Inc. was expected to post a loss of $0.06 per share and delivered exactly that, resulting in no surprise [14]. - The company has not beaten consensus EPS estimates in any of the last four quarters [15]. Conclusion - Quantum Computing Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [18].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Royalty Pharma, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Royalty Pharma is expected to report quarterly earnings of $1.11 per share, reflecting a +6.7% year-over-year change, and revenues of $803.28 million, which is a 9.3% increase from the previous year [3]. - The earnings report is scheduled for November 5, and better-than-expected results could lead to a stock price increase, while a miss may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Royalty Pharma is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.17%, suggesting a bearish sentiment among analysts [12]. Earnings Surprise History - In the last reported quarter, Royalty Pharma had an earnings surprise of +3.64%, reporting $1.14 per share against an expectation of $1.10 [13]. - The company has beaten consensus EPS estimates in the last four quarters [14]. Comparative Analysis - Another company in the biomedical sector, Rhythm Pharmaceuticals, is expected to report a loss of $0.72 per share, with revenues projected at $50.24 million, a 51.1% increase year-over-year [18]. - Rhythm Pharmaceuticals has a positive Earnings ESP of +9.24%, indicating a likelihood of beating consensus EPS estimates, despite only surpassing estimates once in the last four quarters [19][20].

Core Viewpoint - Talos Energy (TALO) is expected to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $0.35 per share and revenues of $428.23 million, down 15.9% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to be released on November 5, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 17.4% lower in the last 30 days, reflecting a bearish sentiment among analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Talos Energy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -18.57%, which complicates predictions of an earnings beat [12]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank, but Talos Energy currently holds a Zacks Rank of 3, making it difficult to predict a positive outcome [10][12]. Historical Performance - In the last reported quarter, Talos Energy was expected to post a loss of $0.27 per share and delivered exactly that, resulting in no surprise [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice, indicating some potential for positive performance [14]. Conclusion - Talos Energy does not appear to be a compelling candidate for an earnings beat based on current estimates and trends, but investors should consider other factors before making decisions regarding the stock [17].